Objective: To study the features of the cytokine status under different forms and variants of PD course.

Background: Parkinson’s disease is clinically heterogeneous; the etiology of the sporadic form is still unclear and only a few molecular mechanisms have been clarified so far in the neurodegenerative cascade. Therefore, the formation of a personalized approach to PD therapy objective biochemical indicators is necessary for more accurate isolation of various PD subtypes and optimize therapy.

Methods: The study included 100 patients – 52 women (52%) and 48 men (48%) aged 41 to 82 years with PD 2.0-4.0 on the Hoehn and Yahr scale. Blood samples were obtained in all patients, samples of CSF in 20 males and 8 females. The content of interleukin (IL) -1β, IL-1 receptor antagonist IL-1RA, IL -10, tumor necrosis factor (TNF) α, IL-6 in the blood serum and CSF was determined by the method enzyme immunoassay.

Results: The study showed that the prevalence of a trembling or akinetic-rigid syndrome in the clinical picture was accompanied by characteristic changes in cytokine status. In patients with the clinically more severe akinetic-rigid form of PD, a decrease is observed of the level of IL-10 in the blood by 20% and an increase in the level of TNF-α in CSF by 1.5 times in comparison with the tremor form irrespective of the stage of the disease. Differences in the cytokine profile of the akinetic-rigid and tremor forms increase at the 3rd and 4th stages of the PD, there is a difference in the level of IL-6 and IL-1PA: these the rates are lower by 64% and 72% in patients with the akinetic-rigid form of PD respectively. in patients with predominantly right-sided clinical symptoms, the level of TNFα in the blood was higher (3.1 (1.4-5.6) pg/ml) than in patients with predominantly left-sided symptoms (1.6 (0-3.1) pg/ml) (p = 0.04). Different rates of PD progression are characterized by a different picture of the cytokine profile: for patients with a rapid rate, the progression of the disease is characterized by an increase in the blood level of IL-1β by 30 % and the level of TNFα by 52 % compared with the slow rate of progression.

Conclusions: Following this approach, it is possible to identify “new” PD subtypes, which is especially important for the identification of previously unknown links in pathogenesis, determining the features of the course of the disease in each subgroup of patients and, as a consequence, to create modern therapeutic strategies

References: Changes in cytokines and neurotrophins in Parkinson’s disease. Nagatsu T, Mogi M, Ichinose H, Togari A. J Neural Transm Suppl. 2000; (60):277-90. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in a ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T. Neurosci Lett. 1996 Jun 14; 211(1):13-6.

« Back to 2018 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/evaluation-clinical-biochemical-features-of-parkinsons-disease/